Skip to content

维斯达控股

US · WAY #2140 按市值排名 上市于 2024
27.36 -0.88 -3.12%
实时 - 追踪5344个代码 - 心跳于306秒前 · 2026-10-16 19:30

估值 各估值倍数与自身5年区间的对比

市净率 1.26 低于历史水平 第25百分位
5年平均 1.70 · 在Health Information Services中排名第13/41
市盈率 37.49 处于历史正常水平 第59百分位
5年平均 -5.68 · 前瞻 24.73 · 在Health Information Services中排名第6/17
市销率 4.17 低于历史水平 第21百分位
5年平均 5.46 · 前瞻 3.74 · 在Health Information Services中排名第28/42

同业对比 Health Information Services

公司 市值 市盈率(TTM) 市净率 股息率
维斯达控股 (WAY) 5.25B 39.09 1.32 0.00%
Veeva Systems (VEEV) 50.25B 50.88 6.76 0.00%
BrightSpring Health Services (BTSG) 12.04B 36.89 5.88 0.00%
Tempus AI (TEM) 11.68B -44.94 26.24 0.00%
Hinge Health (HNGE) 8.00B 74.11 23.24 0.00%
HealthEquity (HQY) 7.61B 33.22 3.83 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★☆☆ 合理价值32.59 经济护城河None 不确定性High

当前股价低于晨星合理价值估算19.1%。

合理价值

While Waystar Holding Corp may seem inexpensive after its substantial price decline over the past year, we've limited its rating to 3 stars to account for the possibility that it may represent a value trap. The stock currently trades at a 19% discount to our quantitative fair value estimate of $32.59 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 83.7% falls in the top 40% globally. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are undervalued.

The firm's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 6.3%, a core component of profitability, ranks in the top 40% compared with peers globally. This suggests that it is generating substantial earnings relative to its share price, which further promotes our favorable price/fair value ratio.

经济护城河

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

维斯达控股 讨论区 0 条评论

发表评论